MarketPulse

bitopertin

6 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Disc Medicine Stock Crashes 22% After FDA Rejects Bitopertin; Class Action Looms

FDA rejected Disc Medicine's bitopertin drug application on February 13, 2026, triggering a 22% stock plunge. The Rosen Law Firm investigates potential securities claims for affected shareholders.
IRONstock declineinvestor losses
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Disc Medicine Stock Crashes 22% After FDA Rejects Bitopertin Application

Disc Medicine ($IRON) shares fell 22% after FDA rejected its bitopertin drug application, prompting class action investigation into securities claims.
IRONsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Pomerantz Llp

Disc Medicine Stock Plummets After FDA Rejects Bitopertin Application

Disc Medicine stock tumbled 30% after FDA rejected bitopertin drug application, prompting securities fraud investigation by Pomerantz LLP.
IRONsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Portnoy Law Firm

Disc Medicine Stock Plummets 22% as FDA Rejects Lead Drug, Triggering Securities Probe

Disc Medicine faces securities probe after FDA rejects bitopertin drug; stock slides 22% on February 13, 2026.
IRONsecurities fraudstock decline
GlobeNewswire Inc.GlobeNewswire Inc.··Pomerantz Llp

Disc Medicine Stock Collapses on FDA Rejection; Law Firm Probes Securities Fraud

Pomerantz LLP investigates Disc Medicine ($IRON) for potential securities fraud after FDA rejected bitopertin drug application, triggering consecutive stock declines totaling over 28%.
IRONsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Disc Medicine Stock Plunges 22% After FDA Rejects Bitopertin Drug Application

FDA rejects Disc Medicine's bitopertin drug, triggering 22% stock decline and securities investigation into potential investor losses.
IRONsecurities fraudclass action lawsuit